Autoimmune Neurogenic Dysphagia

Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.

Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487–98.

Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734–47.

Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360–74.

Labeit B, Pawlitzki M, Ruck T, Muhle P, Claus I, Suntrup-Krueger S, et al. The impact of dysphagia in myositis: a systematic review and meta-analysis. JCM. 2020;9:2150.

Dobloug C, Garen T, Bitter H, Stjärne J, Stenseth G, Grøvle L, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74:1551–6.

Ríos G. Retrospective review of the clinical manifestations and outcomes in puerto ricans with idiopathic inflammatory myopathies. JCR J Clin Rheumatol. 2005;11:153–6.

Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28.

Sheehan NJ. Dysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseases. Rheumatology. 2008;47:746–52.

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77:30–9.

Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Basford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7.

Triplett JD, Pinto MV, Hosfield EA, Milone M, Liewluck T. Myopathies featuring early or prominent dysphagia. Muscle Nerve. 2020;62:344–50.

Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.

Dalakas MC. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. J Neurol Neurosurg Psychiatry. 2016;87:1037.

Dalakas MC. Are autoantibodies pathogenic in necrotizing myopathy? Nat Rev Rheumatol. 2018;14:251–2.

Dalakas MC. Case 22–2019: a 65-year-old woman with myopathy. N Engl J Med. 2019;381:1693.

Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75.

Taira K, Yamamoto T, Mori-Yoshimura M, Fujita S, Oya Y, Nishino I, et al. Obstruction-related dysphagia in inclusion body myositis: cricopharyngeal bar on videofluoroscopy indicates risk of aspiration. J Neurol Sci. 2020;413:116764.

Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009–13.

Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope. 1998;108:1001–5.

Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6.

Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542–5.

Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43:1241–1.

Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989;112:727–47.

Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536–44.

Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm. 2019;6:e581.

Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123–5.

Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73:913–20.

McMillan RA, Bowen AJ, Bayan SL, Kasperbauer JL, Ekbom DC. Cricopharyngeal myotomy in inclusion body myositis: comparison of endoscopic and transcervical approaches. Laryngoscope. 2021. https://doi.org/10.1002/lary.29444.

Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883–9.

Murata K, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep. 2013;6:CCRep.S10200.

Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. IJGM. 2019;12:465–74.

Zeng R, Schmidt J. Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep. 2020;22:74.

Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000;55:296–8.

Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453–77.

Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–8.

Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handbook of Clinical Neurology [Internet]. Elsevier; 2016 [cited 2020 Sep 21]. p. 447–66. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780444634320000244

Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978–80.

Murray JP. Deglutition in myasthenia gravis. BJR. 1962;35:43–52.

Llabres M. Dysphagia as the sole manifestation of myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76:1297–300.

Huang MH, King KL, Chien KY. Esophageal manometric studies in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 1988;95:281–5.

Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505:472–99.

Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology*. Incidence of myasthenia gravis in the Emilia-Romagna region: A prospective multicenter study. Neurology. 1998;51: 255–8.

Carpenter RJ, Mcdonald TJ, Howard FM. The otolaryngologic presentation of myasthenia gravis. Laryngoscope. 1979;89:922???928.

Arellano-Aguilar G, Núñez-Mojica ES, Gutiérrez-Velazco JL, Domínguez-Carrillo LG. Paraneoplastic Lambert-Eaton syndrome in a patient with disseminated metastatic cancer. CIRUE. 2019;86:1948.

Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113–24.

Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology. 1997;48:64S-9S.

Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16:601–17.

Lünemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34–46.

Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57–65.

Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64:1519–23.

Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–44.

Arakawa M, Yamazaki M, Toda Y, Ozawa A, Kimura K. An oculopharyngeal subtype of Guillain-Barré syndrome sparing the trochlear and abducens nerves. Intern Med. 2020;59:1215–7.

Patel K, Nussbaum E, Sico J, Merchant N. Atypical case of Miller-Fisher syndrome presenting with severe dysphagia and weight loss. BMJ Case Rep. 2020;13:e234316.

Edvardsson B, Persson S. Polyneuritis cranialis presenting with anti-GQ1b IgG antibody. J Neurol Sci. 2009;281:125–6.

Ilyas AA, Cook SD, Mithen FA, Taki T, Kasama T, Handa S, et al. Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome. J Neuroimmunol. 1998;82:160–7.

Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Muñoz-Jordan JL, et al. Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018;75:1089.

Orlikowski D, Terzi N, Blumen M, Sharshar T, Raphael JC, Annane D, et al. Tongue weakness is associated with respiratory failure in patients with severe Guillain-Barré syndrome. Acta Neurol Scand. 2009;119:364–70.

Chen MYM, Donofrio PD, Frederick MG, Ott DJ, Pikna LA. Videofluoroscopic evaluation of patients with Guillain-Barré syndrome. Dysphagia. 1996;11:11–3.

Mengi T, Seçil Y, İncesu TK, Arici Ş, Akkiraz ZÖ, Gürgör N, et al. Guillain-Barré syndrome and swallowing dysfunction. J Clin Neurophysiol. 2017;34:393–9.

Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19–triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7:e781.

Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity. Neurology. 2020;95:195–6.

Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2010 [cited 2020 Sep 27]. p. CD002063.pub4. Available from: http://doi.wiley.com/https://doi.org/10.1002/14651858.CD002063.pub4

Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–75.

Teramoto H, Morita A, Hara M, Ninomiya S, Shigihara S, Kusunoki S, et al. Relapse with dysphagia in a case of chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med. 2015;54:1791–3.

Mazzucco S, Ferrari S, Mezzina C, Tomelleri G, Bertolasi L, Rizzuto N. Hyperpyrexia-triggered relapses in an unusual case of ataxic chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Sci. 2006;27:176–9.

Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.

van Schaik IN, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46.

Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010;81:634–6.

Dyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35:1173–6.

Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012;18:463–8.

Zekeridou A, Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc. 2019;94:1865–78.

Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you “take the brakes off” the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.

Muppidi S, Vernino S. Paraneoplastic neuropathies. Continuum (Minneap Minn). 2014;20:1359–72.

Graus F, Dalmau J. Paraneoplastic neuropathies. Curr Opin Neurol. 2013;26:489–95.

Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67:7–14.

Viala K, Béhin A, Maisonobe T, Léger J-M, Stojkovic T, Davi F, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008;79:778–82.

Ni J, Weng L, Liu M, Yang H, Wang Y. Small cell lung cancer accompanied by tonsillar metastasis and anti-hu antibody-associated paraneoplastic neuropathy: a rare case report with long-term survival. Medicine. 2015;94:e2291.

Yeung JC, Pringle CE, Sekhon HS, Kilty SJ, Macdonald K. Bilateral vocal cord paralysis and cervicolumbar radiculopathy as the presenting paraneoplastic manifestations of small cell lung cancer: a case report and literature review. Case Rep Otolaryngol. 2016;2016:1–5.

Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580–7.

Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16:2–15.

Brito-Zerón P, Bari K, Baughman RP, Ramos-Casals M. Sarcoidosis involving the gastrointestinal tract: diagnostic and therapeutic management. Am J Gastroenterol. 2019;114:1238–47.

Nishikubo K, Hyodo M, Kawakami M, Kobayashi T. A rare manifestation of cricopharyngeal myopathy presenting with dysphagia in sarcoidosis. Rheumatol Int. 2013;33:1089–92.

Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732.

Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al. Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39:27–33.

Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82:798–802.

Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41:203–11.

Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J. 1979;2:173–5.

Poglio F, Mongini T, Cocito D. Sensory ataxic neuropathy and esophageal achalasia in a patient with Sjogren’s syndrome. Muscle Nerve. 2007;35:532–5.

Sanchez JMS, McNally JS, Cortez MM, Hemp J, Pace LA, Clardy SL. Neuroimmunogastroenterology: at the interface of neuroimmunology and gastroenterology. Front Neurol. 2020;11:787.

Dhamija R, Tan KM, Pittock SJ, Foxx-Orenstein A, Benarroch E, Lennon VA. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol. 2008;6:988–92.

Mukaino A, Minami H, Isomoto H, Hamamoto H, Ihara E, Maeda Y, et al. Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. J Gastroenterol. 2018;53:1227–40.

D’Amico E, Zanghì A, Serra A, Murabito P, Zappia M, Patti F, et al. Management of dysphagia in multiple sclerosis: current best practice. Expert Rev Gastroenterol Hepatol. 2019;13:47–54.

Tassorelli C, Bergamaschi R, Buscone S, Bartolo M, Furnari A, Crivelli P, et al. Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci. 2008;29:360–3.

Pender MP, Ferguson SM. Dysarthria and dysphagia due to the opercular syndrome in multiple sclerosis. Mult Scler. 2007;13:817–9.

Guan X-L, Wang H, Huang H-S, Meng L. Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2015;36:671–81.

Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49:253–71.

Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46:9–17.

Levinthal DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:1–9.

Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, et al. Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). J Neurol Sci. 2013;331:94–7.

Danesh-Sani SA, Rahimdoost A, Soltani M, Ghiyasi M, Haghdoost N, Sabzali-Zanjankhah S. Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. J Oral Maxillofac Surg. 2013;71:290–4.

Abraham S, Scheinberg LC, Smith CR, LaRocca NG. Neurologic impairment and disability status in outpatients with multiple sclerosis reporting dysphagia symptomatology. Neurorehabil Neural Repair. 1997;11:7–13.

De Pauw A, Dejaeger E, D’hooghe B, Carton H. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg. 2002;104:345–51.

Fernandes AMF, de Campos DA, Eckley CA, da Silva L, Ferreira RB, Tilbery CP. Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity? Braz J Otorhinolaryngol. 2013;79:460–5.

Alfonsi E, Bergamaschi R, Cosentino G, Ponzio M, Montomoli C, Restivo DA, et al. Electrophysiological patterns of oropharyngeal swallowing in multiple sclerosis. Clin Neurophysiol. 2013;124:1638–45.

Wiesner W, Wetzel SG, Kappos L, Hoshi MM, Witte U, Radue EW, et al. Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. Eur Radiol. 2002;12:789–92.

Terré-Boliart R, Orient-López F, Guevara-Espinosa D, Ramón-Rona S, Bernabeu-Guitart M. Clavé-Civit P [Oropharyngeal dysphagia in patients with multiple sclerosis]. Rev Neurol. 2004;39:707–10.

Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752–9.

Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636.

He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16.

Restivo DA, Marchese-Ragona R, Patti F. Management of swallowing disorders in multiple sclerosis. Neurol Sci. 2006;27:s338-40.

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7.

O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211–7.

Chan KH. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432.

Koda A, Kaneko S, Asayama S, Fujita K, Kusaka H. Successful treatment of neuromyelitis optica spectrum disorder by early initiation of plasma exchange. Rinsho Shinkeigaku. 2015;55:41–4.

Cousins O, Girelli E, Harikrishnan S. Neuromyelitis optica: an elusive cause of dysphagia. BMJ Case Rep. 2019;12:bcr-2018-227041.

Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79:1075–8.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.

Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, Peschl P, et al. Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol. 2019;137:467–85.

Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS ONE. 2011;6:e27412.

Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, et al. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014;261:954–62.

Pawlitzki M, Ahring S, Rolfes L, Dziewas R, Warnecke T, Suntrup‐Krueger S, et al. Dysphagia in NMOSD and MOGAD as a surrogate of brain involvement? Eur J Neurol. 2020;ene.14691. https://doi.org/10.1111/ene.14691.

Sonies BC, Dalakas MC. Dysphagia in patients with the post-polio syndrome. N Engl J Med. 1991;324:1162–7.

Huh S-Y, Kim S-H, Hyun J-W, Joung A-R, Park MS, Kim B-J, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372.

Kim S-H, Jeong IH, Hyun J-W, Joung A, Jo H-J, Hwang S-H, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–63.

Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–25.

Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131.

Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.

Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021;14:17562864211003486.

Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. 2019;19:1.

Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67:1068–70.

Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178–92.

Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013;81:1962–4.

Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–6.

Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82:271–7.

RamachandranNair R, Manoj P, Rafeequ M, Girija AS. Childhood acute disseminated encephalomyelitis presenting as Foix-Chavany-Marie syndrome. J Child Neurol. 2005;20:163–5.

Pittard A, Abramo TJ, Arnold DH. A child with difficulty swallowing. Pediatr Emerg Care. 2009;25:525–8.

Ma Y, Sun X, Li W, Li Y, Kang T, Yang X, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with intracranial Epstein-Barr virus infection: a case report. Medicine. 2016;95:e5377.

Mundiyanapurath S, Jarius S, Probst C, Stöcker W, Wildemann B, Bösel J. GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol. 2013;259:88–91.

Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–803.

Oz Tuncer G, Teber S, Kutluk MG, Albayrak P, Deda G. Hashimoto’s encephalopathy presenting as pseudobulbar palsy. Childs Nerv Syst. 2018;34:1251–4.

Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126:2279–90.

Michev A, Musso P, Foiadelli T, Trabatti C, Lozza A, Franciotta D, et al. Bickerstaff brainstem encephalitis and overlapping Guillain-Barré syndrome in children: report of two cases and review of the literature. Eur J Paediatr Neurol. 2019;23:43–52.

Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43.

Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385.

Li X-L, Han J, Zhao H-T, Long Y-M, Zhang B-W, Wang H-Y. Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord. Ther Adv Neurol Disord. 2020;13:175628642090997.

Shelly S, Kryzer TJ, Komorowski L, Miske R, Anderson MD, Flanagan EP, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2019;6:e612.

Wallwitz U, Brock S, Schunck A, Wildemann B, Jarius S, Hoffmann F. From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. J Neuroimmunol. 2017;309:77–81.

Castle J, Sakonju A, Dalmau J, Newman-Toker DE. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple’s disease. Nat Rev Neurol. 2006;2:566–72.